BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
about
Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells.BIRC5 is a novel target of peroxisome proliferator‑activated receptor γ in brain microvascular endothelium cells during cerebral ischemia.Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.Identification of genes and analysis of prognostic values in nonsmoking females with non-small cell lung carcinoma by bioinformatics analyses
P2860
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
BIRC5 (survivin): a pejorative ...... e to neoadjuvant chemotherapy.
@en
BIRC5
@nl
type
label
BIRC5 (survivin): a pejorative ...... e to neoadjuvant chemotherapy.
@en
BIRC5
@nl
prefLabel
BIRC5 (survivin): a pejorative ...... e to neoadjuvant chemotherapy.
@en
BIRC5
@nl
P2093
P2860
P50
P1476
BIRC5 (survivin): a pejorative ...... e to neoadjuvant chemotherapy.
@en
P2093
B Asselain
B Sigal-Zafrani
F Spyratos
J M Guinebretière
M C Matthieu
Ph Bertheau
P2860
P2888
P304
P356
10.1007/S10549-016-3961-2
P407
P577
2016-09-03T00:00:00Z